{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:31:22Z","timestamp":1782178282037,"version":"3.54.5"},"reference-count":134,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.hoc.2021.08.009","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T03:52:29Z","timestamp":1635479549000},"page":"189-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Leptomeningeal Disease"],"prefix":"10.1016","volume":"36","author":[{"given":"Yolanda","family":"Pi\u00f1a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Gramatzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudocia Q.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2021.08.009_bib1","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib2","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1215\/15228517-2008-062","article-title":"Prognostic factors and outcomes in patients with leptomeningeal melanomatosis","volume":"10","author":"Harstad","year":"2008","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0733-8619(02)00032-4","article-title":"Leptomeningeal metastases","volume":"21","author":"Kesari","year":"2003","journal-title":"Neurol Clin"},{"key":"10.1016\/j.hoc.2021.08.009_bib4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1215\/15228517-2007-058","article-title":"Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features","volume":"10","author":"Raizer","year":"2008","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib5","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","article-title":"Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis","volume":"26","author":"Brastianos","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2021.08.009_bib6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11060-013-1244-x","article-title":"Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa","volume":"115","author":"Comte","year":"2013","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11060-010-0524-y","article-title":"Meningeal carcinomatosis in breast cancer: prognostic factors and outcome","volume":"104","author":"de Azevedo","year":"2011","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib8","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/annonc\/mdq232","article-title":"Survival of breast cancer patients with meningeal carcinomatosis","volume":"21","author":"Gauthier","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/pcmr.12861","article-title":"Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions","volume":"33","author":"Glitza","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.hoc.2021.08.009_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-013-1092-8","article-title":"A\u00a0retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer","volume":"113","author":"Le Rhun","year":"2013","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-007-9340-4","article-title":"Breast cancer leptomeningeal metastasis--the role of multimodality treatment","volume":"84","author":"Rudnicka","year":"2007","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11060-017-2452-6","article-title":"Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe","volume":"133","author":"Le Rhun","year":"2017","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib13","doi-asserted-by":"crossref","unstructured":"Deangelis LM, Posner JB. Neurologic Complications of Cancer. 2nd ed. Contemporary Neurology Series, 240-281. New York: Oxford University Press; 2009.","DOI":"10.1093\/med\/9780195366747.003.0007"},{"key":"10.1016\/j.hoc.2021.08.009_bib14","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.seminoncol.2009.05.005","article-title":"Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment","volume":"36","author":"Chamberlain","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/CMR.0000000000000274","article-title":"A\u00a0rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature","volume":"26","author":"Fedorenko","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.hoc.2021.08.009_bib16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2019.05.019","article-title":"Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors","volume":"116","author":"Hendriks","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hoc.2021.08.009_bib17","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.4103\/2152-7806.111304","article-title":"Carcinomatous meningitis: Leptomeningeal metastases in solid tumors","volume":"4","author":"Le Rhun","year":"2013","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.hoc.2021.08.009_bib18","first-page":"579","article-title":"Intracranial metastases from systemic cancer","volume":"19","author":"Posner","year":"1978","journal-title":"Adv Neurol"},{"key":"10.1016\/j.hoc.2021.08.009_bib19","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/cncr.21322","article-title":"Leptomeningeal metastases from small cell lung carcinoma","volume":"104","author":"Seute","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2021.08.009_bib20","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ijc.30147","article-title":"Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy","volume":"139","author":"Smalley","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.hoc.2021.08.009_bib21","first-page":"984","article-title":"Risk for leptomeningeal seeding after resection for brain metastases: implication of tumor location with mode of resection","volume":"116","author":"Ahn","year":"2012","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.hoc.2021.08.009_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10585-020-10019-1","article-title":"Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis","volume":"37","author":"Brown","year":"2020","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.hoc.2021.08.009_bib23","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0b013e3181dc1a69","article-title":"Leptomeningeal metastases in the MRI era","volume":"74","author":"Clarke","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.hoc.2021.08.009_bib24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(06)70443-4","article-title":"Neoplastic meningitis","volume":"5","author":"Gleissner","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.hoc.2021.08.009_bib25","unstructured":"Posner, L.M.D.a.J.B. Neurologic Complications of Cancer. 240-281 (2009)."},{"key":"10.1016\/j.hoc.2021.08.009_bib26","doi-asserted-by":"crossref","first-page":"E152","DOI":"10.1093\/neuros\/nyy542","article-title":"Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Surgery in the Management of Adults With Metastatic Brain Tumors","volume":"84","author":"Nahed","year":"2019","journal-title":"Neurosurgery"},{"key":"10.1016\/j.hoc.2021.08.009_bib27","first-page":"1132","article-title":"Impact of surgical methodology on the complication rate and functional outcome of patients with a single brain metastasis","volume":"122","author":"Patel","year":"2015","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.hoc.2021.08.009_bib28","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijrobp.2015.11.022","article-title":"Surgical Resection of Brain Metastases and the Risk of Leptomeningeal Recurrence in Patients Treated With Stereotactic Radiosurgery","volume":"94","author":"Johnson","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2021.08.009_bib29","doi-asserted-by":"crossref","first-page":"17758","DOI":"10.1038\/srep17758","article-title":"Surgical Ventricular Entry is a Key Risk Factor for Leptomeningeal Metastasis of High Grade Gliomas","volume":"5","author":"Roelz","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.hoc.2021.08.009_bib30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/jnnp.66.2.225","article-title":"Leptomeningeal metastasis after surgical resection of brain metastases","volume":"66","author":"van der Ree","year":"1999","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.hoc.2021.08.009_bib31","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/neuros\/nyy202","article-title":"Cancer Dissemination, Hydrocephalus, and Survival After Cerebral Ventricular Entry During High-Grade Glioma Surgery: A Meta-Analysis","volume":"83","author":"Mistry","year":"2018","journal-title":"Neurosurgery"},{"key":"10.1016\/j.hoc.2021.08.009_bib32","first-page":"834","article-title":"Ventricular entry during resection of malignant gliomas: effect on intracranial cerebrospinal fluid tumor dissemination","volume":"80","author":"Elliott","year":"1994","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.hoc.2021.08.009_bib33","doi-asserted-by":"crossref","first-page":"E924","DOI":"10.1093\/neuros\/nyz144","article-title":"Comparative Analysis of Subventricular Zone Glioblastoma Contact and Ventricular Entry During Resection in Predicting Dissemination, Hydrocephalus, and Survival","volume":"85","author":"Mistry","year":"2019","journal-title":"Neurosurgery"},{"key":"10.1016\/j.hoc.2021.08.009_bib34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11060-014-1539-6","article-title":"Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery","volume":"120","author":"Huang","year":"2014","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib35","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/neuros\/nyy436","article-title":"Hemorrhagic and Cystic Brain Metastases Are Associated With an Increased Risk of Leptomeningeal Dissemination After Surgical Resection and Adjuvant Stereotactic Radiosurgery","volume":"85","author":"Press","year":"2019","journal-title":"Neurosurgery"},{"key":"10.1016\/j.hoc.2021.08.009_bib36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11060-011-0592-7","article-title":"Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study","volume":"105","author":"Le Rhun","year":"2011","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10549-011-1682-0","article-title":"Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations","volume":"129","author":"Lee","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.hoc.2021.08.009_bib38","unstructured":"Haines, D.E. Neuroanatomy: An Atlas of Structures, Sections, and Systems., 52-63 (2008)."},{"key":"10.1016\/j.hoc.2021.08.009_bib39","unstructured":"Ross, M.H.a.P., Wojciech. Histology: A Text and Atlas with correlated cell and molecular biology., 348 (2006)."},{"key":"10.1016\/j.hoc.2021.08.009_bib40","doi-asserted-by":"crossref","unstructured":"Rea, P. Essential Clinical Anatomy of the Nervous System. 121-131 (2015, Essential Anatomy and Function of the Spinal Cord).","DOI":"10.1016\/B978-0-12-802030-2.00007-8"},{"key":"10.1016\/j.hoc.2021.08.009_bib41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/pgmj.56.653.149","article-title":"Diffuse involvement of the leptomeninges by tumour--a clinical and pathological study of 63 cases","volume":"56","author":"Boyle","year":"1980","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.hoc.2021.08.009_bib42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/1097-0142(19830101)51:1<154::AID-CNCR2820510130>3.0.CO;2-K","article-title":"Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid?","volume":"51","author":"Kokkoris","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2021.08.009_bib43","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1212\/WNL.0000000000000455","article-title":"Teaching NeuroImages: leptomeningeal lung carcinoma","volume":"82","author":"Glover","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.hoc.2021.08.009_bib44","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1097\/00007632-199306150-00013","volume":"18","author":"Wiltse","year":"1993","journal-title":"Spine (Phila Pa 1976)"},{"issue":"1","key":"10.1016\/j.hoc.2021.08.009_bib45","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/2045-8118-11-26","article-title":"Mechanisms of fluid movement into, through and out of the brain: Evaluation of the evidence","volume":"11","author":"Hladky","year":"2014","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.hoc.2021.08.009_bib46","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.aaz2193","article-title":"Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.hoc.2021.08.009_bib47","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1021\/pr7007994","article-title":"Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells","volume":"7","author":"Pitteri","year":"2008","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.hoc.2021.08.009_bib48","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.4161\/cc.8.15.9224","article-title":"Lipocalin 2: a multifaceted modulator of human cancer","volume":"8","author":"Yang","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.hoc.2021.08.009_bib49","doi-asserted-by":"crossref","first-page":"1101.e13","DOI":"10.1016\/j.cell.2017.02.025","article-title":"Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis","volume":"168","author":"Boire","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2021.08.009_bib50","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/neuonc\/nox029","article-title":"The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria","volume":"19","author":"Nayak","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib51","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/neuonc\/noaa030","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases","volume":"22","author":"Kaufmann","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib52","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jocn.2017.07.020","article-title":"Most common sites on MRI of intracranial neoplastic leptomeningeal disease","volume":"45","author":"Debnam","year":"2017","journal-title":"J\u00a0Clin Neurosci"},{"issue":"7","key":"10.1016\/j.hoc.2021.08.009_bib53","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/neuonc\/noaa298","article-title":"Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors","volume":"23","author":"Le Rhun","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib54","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cllc.2013.12.009","article-title":"Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era","volume":"15","author":"Riess","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.hoc.2021.08.009_bib55","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s12032-012-0408-4","article-title":"Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival","volume":"30","author":"Niwinska","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-013-1175-6","article-title":"Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis","volume":"114","author":"Yust-Katz","year":"2013","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clbc.2016.07.002","article-title":"Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis","volume":"17","author":"Morikawa","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.hoc.2021.08.009_bib58","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11060-018-2790-z","article-title":"Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM)","volume":"138","author":"Niwi\u0144ska","year":"2018","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib59","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.lungcan.2011.11.022","article-title":"Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era","volume":"76","author":"Park","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.hoc.2021.08.009_bib60","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.lungcan.2012.03.002","article-title":"Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group","volume":"77","author":"Umemura","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.hoc.2021.08.009_bib61","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","article-title":"Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy","volume":"7","author":"Morris","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib62","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/annonc\/mdw134","article-title":"Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma","volume":"27","author":"Geukes Foppen","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib63","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2214\/ajr.153.5.1039","article-title":"MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis","volume":"153","author":"Sze","year":"1989","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.hoc.2021.08.009_bib64","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1148\/radiology.174.1.2294579","article-title":"Meninges: benign postoperative enhancement on MR images","volume":"174","author":"Burke","year":"1990","journal-title":"Radiology"},{"key":"10.1016\/j.hoc.2021.08.009_bib65","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1148\/radiology.211.1.r99mr25257","article-title":"Brain: gadolinium-enhanced fast fluid-attenuated inversion-recovery MR imaging","volume":"211","author":"Mathews","year":"1999","journal-title":"Radiology"},{"key":"10.1016\/j.hoc.2021.08.009_bib66","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0002-9343(82)90404-1","article-title":"Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography","volume":"73","author":"Grossman","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.hoc.2021.08.009_bib67","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/1097-0142(19950615)75:12<2919::AID-CNCR2820751220>3.0.CO;2-9","article-title":"Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status","volume":"75","author":"Glantz","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2021.08.009_bib68","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib69","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/A:1005982826121","article-title":"Radioisotope CSF flow studies in leptomeningeal metastases","volume":"38","author":"Chamberlain","year":"1998","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib70","first-page":"2057","article-title":"Prolonged survival of patients with breast cancer-related leptomeningeal metastases","volume":"33","author":"Le Rhun","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.hoc.2021.08.009_bib71","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/neuonc\/noz208","article-title":"A\u00a0retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer","volume":"22","author":"Nevel","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib72","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","article-title":"High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?","volume":"16","author":"Glantz","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib73","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0022-510X(94)90159-7","article-title":"A\u00a0standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid","volume":"121","author":"Dux","year":"1994","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.hoc.2021.08.009_bib74","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/WNL.42.6.1239","article-title":"Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis","volume":"42","author":"Rogers","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.hoc.2021.08.009_bib75","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1212\/WNL.0000000000008751","article-title":"Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases","volume":"94","author":"van Bussel","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.hoc.2021.08.009_bib76","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/neuonc\/nox066","article-title":"Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors","volume":"19","author":"Lin","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib77","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11060-020-03555-z","article-title":"Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer","volume":"148","author":"Malani","year":"2020","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib78","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdy009","article-title":"Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy","volume":"29","author":"Li","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib79","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11523-019-00645-5","article-title":"Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases","volume":"14","author":"Huang","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib80","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jtho.2019.01.007","article-title":"Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC","volume":"14","author":"Zheng","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib81","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/15384047.2018.1538614","article-title":"Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases","volume":"20","author":"Ying","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.hoc.2021.08.009_bib82","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib83","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejca.2021.02.016","article-title":"Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities","volume":"148","author":"Chorti","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hoc.2021.08.009_bib84","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib85","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdw641","article-title":"Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study","volume":"28","author":"McArthur","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib86","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11864-020-00759-3","article-title":"Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations","volume":"21","author":"Alexander","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib87","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2015.05.023","article-title":"Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis","volume":"89","author":"Kuiper","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.hoc.2021.08.009_bib88","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations","volume":"11","author":"Li","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib89","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study","volume":"38","author":"Yang","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib90","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non\u2013Small-Cell Lung Cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib91","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.annonc.2020.06.017","article-title":"A\u00a0phase II, multicenter, two cohort study of 160\u00a0mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy","volume":"31","author":"Park","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib92","first-page":"41","article-title":"Leptomeningeal metastases from non-small cell lung cancer: state of the art and recent advances","volume":"6","author":"Pellerino","year":"2020","journal-title":"J\u00a0Cancer Metastasis Treat"},{"key":"10.1016\/j.hoc.2021.08.009_bib93","doi-asserted-by":"crossref","first-page":"v143","DOI":"10.1093\/annonc\/mdz243","article-title":"Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study","volume":"30","author":"Barlesi","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib94","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/JTO.0000000000000455","article-title":"Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib","volume":"10","author":"Gainor","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib95","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study","volume":"29","author":"Gadgeel","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib96","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.20.00505","article-title":"Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial","volume":"38","author":"Camidge","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib97","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","article-title":"Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer","volume":"15","author":"Bauer","year":"2020","journal-title":"Target Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib98","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920980558","article-title":"Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program","volume":"13","author":"Frost","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib99","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11060-007-9409-0","article-title":"Capecitabine therapy of central nervous system metastases from breast cancer","volume":"85","author":"Ekenel","year":"2007","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.clbc.2019.04.004","article-title":"Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer","volume":"19","author":"Mrugala","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"suppl_6","key":"10.1016\/j.hoc.2021.08.009_bib101","doi-asserted-by":"crossref","first-page":"vi57","DOI":"10.1093\/neuonc\/noy148.232","article-title":"CMET-20. Evidence of cns response of pembrolizumab for leptomeningeal carcinomatosis at a single cell resolution","volume":"20","author":"Alvarez-Breckenridge","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib102","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","article-title":"ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases","volume":"26","author":"Kumthekar","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2021.08.009_bib103","doi-asserted-by":"crossref","first-page":"CNS65","DOI":"10.2217\/cns-2020-0023","article-title":"Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review","volume":"9","author":"Fernandes","year":"2020","journal-title":"CNS Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib104","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1158\/1078-0432.CCR-20-1764","article-title":"A\u00a0Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer","volume":"26","author":"Tolaney","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2021.08.009_bib105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41582-020-0391-x","article-title":"Management of brain metastases according to molecular subtypes","volume":"16","author":"Soffietti","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.hoc.2021.08.009_bib106","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1158\/1078-0432.CCR-18-3502","article-title":"Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases","volume":"25","author":"Morikawa","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2021.08.009_bib107","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.18.01511","article-title":"TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases","volume":"37","author":"Freedman","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib108","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.annonc.2020.05.014","article-title":"Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases","volume":"31","author":"Metzger Filho","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib109","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","volume":"382","author":"Murthy","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2021.08.009_bib110","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2021.08.009_bib111","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/neuonc\/noaa152","article-title":"Clinical trial of proton craniospinal irradiation for leptomeningeal metastases","volume":"23","author":"Yang","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib112","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.2006.09.9861","article-title":"Chemotherapy delivery issues in central nervous system malignancy: a reality check","volume":"25","author":"Muldoon","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib113","doi-asserted-by":"crossref","first-page":"e000507","DOI":"10.1136\/esmoopen-2019-000507","article-title":"How we treat patients with leptomeningeal metastases","volume":"4","author":"Le Rhun","year":"2019","journal-title":"ESMO open"},{"key":"10.1016\/j.hoc.2021.08.009_bib114","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/neuonc\/noz201","article-title":"Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer","volume":"22","author":"Le Rhun","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2018.02.032","article-title":"Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis","volume":"95","author":"Bonneau","year":"2018","journal-title":"Eur J Cancer"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2021.08.009_bib116","doi-asserted-by":"crossref","first-page":"i6","DOI":"10.1093\/noajnl\/vdz014.025","article-title":"LPTO-02. intrathecal (IT) trastuzumab (T) for the treatment of leptomeningeal disease (LM) in patients (PTS) with human epidermal receptor-2 positive (HER2+) cancer: a multicenter phase 1\/2 study","volume":"1","author":"Kumthekar","year":"2019","journal-title":"Neuro Oncol Adv"},{"key":"10.1016\/j.hoc.2021.08.009_bib117","doi-asserted-by":"crossref","first-page":"e000283","DOI":"10.1136\/esmoopen-2017-000283","article-title":"Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2","volume":"3","author":"Glitza","year":"2018","journal-title":"ESMO Open"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2021.08.009_bib118","doi-asserted-by":"crossref","first-page":"10008","DOI":"10.1200\/JCO.2020.38.15_suppl.10008","article-title":"Single-center phase I\/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD)","volume":"38","author":"Glitza","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib119","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/neuonc\/noz024","article-title":"The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal","volume":"21","author":"Le Rhun","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11060-018-2949-7","article-title":"Management of hydrocephalus in patients with leptomeningeal metastases: an ethical approach to decision-making","volume":"140","author":"Lamba","year":"2018","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib121","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.breast.2017.07.015","article-title":"Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience","volume":"36","author":"Kingston","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.hoc.2021.08.009_bib122","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/JTO.0b013e3182773f21","article-title":"Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors","volume":"8","author":"Lee","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib123","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jtho.2019.05.007","article-title":"Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases","volume":"14","author":"Flippot","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib124","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2004.05.008","article-title":"Leptomeningeal metastasis: survival and prognostic factors in 155 patients","volume":"223","author":"Herrlinger","year":"2004","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.hoc.2021.08.009_bib125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2015.12.021","article-title":"Leptomeningeal metastasis: Clinical experience of 519 cases","volume":"56","author":"Hyun","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hoc.2021.08.009_bib126","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/JTO.0b013e318287c943","article-title":"Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer","volume":"8","author":"Gwak","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib127","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-014-3054-z","article-title":"Leptomeningeal disease and breast cancer: the importance of tumor subtype","volume":"146","author":"Abouharb","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.hoc.2021.08.009_bib128","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-016-2179-9","article-title":"Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors","volume":"129","author":"Ozdemir","year":"2016","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib129","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3389\/fonc.2018.00641","article-title":"Palliative Radiotherapy for Leptomeningeal Carcinomatosis-Analysis of Outcome, Prognostic Factors, and Symptom Response","volume":"8","author":"El Shafie","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib130","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s12885-020-06984-1","article-title":"Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting","volume":"20","author":"Devecka","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hoc.2021.08.009_bib131","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JCO.1993.11.3.561","article-title":"Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group","volume":"11","author":"Grossman","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib132","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.1987.5.10.1655","article-title":"A\u00a0prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis","volume":"5","author":"Hitchins","year":"1987","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2021.08.009_bib133","first-page":"3394","article-title":"A\u00a0randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"5","author":"Glantz","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2021.08.009_bib134","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.ejca.2004.08.012","article-title":"The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study","volume":"40","author":"Boogerd","year":"2004","journal-title":"Eur J Cancer"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882100112X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882100112X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:17:24Z","timestamp":1760185044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985882100112X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":134,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S088985882100112X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2021.08.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leptomeningeal Disease","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2021.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}